Ibrutinib promotes atrial fibrillation by inducing structural remodeling and calcium dysregulation in the atrium

Ibrutinib is a novel anti-tumor drug that targets Bruton ’s tyrosine kinase (BTK) for the treatment of chronic lymphocytic leukemia. Atrial fibrillation (AF) occurs in 5—9% of patients during treatment, but the underlying mechanisms remain unclear.

Source: Heart Rhythm - April 4, 2019 Category: Cardiology Authors: Le Jiang, Linling Li, Yanfei Ruan, Song Zuo, Xiaoyan Wu, Qianqian zhao, Yanwei Xing, Xin Zhao, Shijun Xia, Rong Bai, Xin Du, Nian Liu, ChangSheng Ma Source Type: research